ライフサイエンスコーパス: herpetic

1 its therapeutic potential, particularly for herpetic and Acanthamoeba keratitis.

2 medical subject headings (MESH) "Keratitis, Herpetic/" AND "Acyclovir/" limiting by the key words "t

3 lar pressure (IOP) and secondary glaucoma in herpetic anterior uveitis (AU), owing to either herpes s

4 ained unchanged after exclusion of eyes with herpetic anterior uveitis.

5 Seventy-three herpetic AU patients were included.

6 Patients with herpetic AU presenting themselves between 2001 and 2013

7 econdary glaucoma are major complications in herpetic AU.

8 in the local trigeminal ganglion and reduced herpetic blepharitis and corneal scarring.

9 In the current study, a rabbit herpetic corneal endotheliitis model was made of induced

10 as a reduction in the incidence of recurrent herpetic corneal epithelial disease and stromal disease

11 3.1 +/- 10.13 years; indications for PK were herpetic corneal scar (53.3%), corneal stromal dystrophy

12 rophylaxis for MK in high-risk, vascularized herpetic corneal scars achieves clinical outcomes that r

13 utive eyes with vascularized (>=2 quadrants) herpetic corneal scars underwent 2-piece microkeratome-a

14 completely protected from local or systemic herpetic disease after intravaginal challenge with wild-

15 glia, the majority never develop a recurrent herpetic disease and remain asymptomatic (ASYMP).

16 ptomatic" antigens (ID-S-Ags) may exacerbate herpetic disease and therefore must be excluded from any

17 ng what differentiates humans with recurrent herpetic disease from the vast majority of asymptomatic

18 nal ganglia (TG) leads to blinding recurrent herpetic disease in symptomatic (SYMP) individuals.

19 nal ganglia (TG) leads to blinding recurrent herpetic disease in symptomatic (SYMP) individuals.

20 olved in protection against recurrent ocular herpetic disease in therapeutically vaccinated animals a

21 n herpes immunity against blinding recurrent herpetic disease is heavily explored, the role of B cell

22 luation in both primary and recurrent ocular herpetic disease models.

23 Fifty subjects without signs of ocular herpetic disease participated.

24 a history of numerous episodes of recurrent herpetic disease) and asymptomatic (ASYMP) individuals (

25 s (individuals who have never had a clinical herpetic disease) has not been elucidated.

26 mptomatic B6 mice (with little to no corneal herpetic disease), compared to corneas of symptomatic mi

27 being infected, never develop any recurrent herpetic disease).

28 individuals (who never had recurrent corneal herpetic disease).

29 infected but never experienced any recurrent herpetic disease).

30 ory of numerous episodes of recurrent ocular herpetic disease).

31 eas of symptomatic mice (with severe corneal herpetic disease).

32 ry of numerous episodes of recurrent corneal herpetic disease, compared to asymptomatic patients who

33 ng infected, never experienced any recurrent herpetic disease, remains to be fully elucidated.

34 ividuals who never experienced any recurrent herpetic disease, symptomatic (SYMP) individuals have a

35 a history of numerous episodes of recurrent herpetic disease, using the high-throughput digital Nano

36 sitive for HSV-1 but never had any recurrent herpetic disease, while there were frequent less-differe

37 c potential to reduce or eliminate recurrent herpetic disease.

38 n in virus reactivation and recurrent ocular herpetic disease.

39 asymptomatic patients who never had corneal herpetic disease.

40 ches to reducing susceptibility to recurrent herpetic disease.

41 ent likely to reduce long-term scarring from herpetic disease.

42 being infected, never develop any recurrent herpetic disease.

43 ory of numerous episodes of recurrent ocular herpetic disease.

44 1) potentially leading to blinding recurrent herpetic disease.

45 in tears that trigger the recurrent corneal herpetic disease.

46 in both virus shedding and recurrent corneal herpetic disease.

47 cause potentially blinding recurrent corneal herpetic disease.

48 ding in tears that trigger recurrent corneal herpetic disease.

49 to the clinical findings and the history of herpetic disease.

50 ersely, HIV-1 is associated with more-severe herpetic disease.

51 SV-1 reactivation from latency and recurrent herpetic disease.

52 uals (individuals who have frequent clinical herpetic diseases) using determination of a combination

53 gh potential as an alternative treatment for herpetic diseases.

54 hosphonoformic acid, a specific inhibitor of herpetic DNA polymerase.

55 action of the acyclic alpha-CNPs against the herpetic DNA polymerases differs from the nature of the

56 ft of approximately 100-fold in favor of the herpetic DNA polymerases when compared to selectivity fo

57 to 100-fold) inhibits HIV-1 RT compared with herpetic DNA polymerases.

58 Acyclovir (ACV), a highly specific anti-herpetic drug, acts as a DNA chain terminator for severa

59 ster prodrug of acyclovir, an effective anti-herpetic drug.

60 f new safe and effective broad spectrum anti-herpetic drugs that fill an unmet need.

61 , heightened susceptibility of muK/O mice to herpetic encephalitis as well as to herpetic stromal ker

62 the central nervous system (CNS) and causing herpetic encephalitis.

63 The morbidity from recurrent herpetic episodes is high, and the resultant corneal sca

64 ate for improving antiviral efficacy against herpetic epithelial and stromal keratitis.

65 rus (HSV) from neuron to epithelial cells in herpetic epithelial keratitis.

66 Herpetic eye disease (due to herpes simplex and herpes z

67 opathies, retinal conditions, scleritis, and herpetic eye disease have also been highlighted.

68 results could help support the diagnosis of herpetic eye disease in these patients.

69 RELEVANCE The association between atopy and herpetic eye disease may be explained by various factors

70 The Herpetic Eye Disease Study (HEDS) I showed a significant

71 Between 1993 and 1997, the Herpetic Eye Disease Study (HEDS) randomized 703 partici

72 episodes of HSV have been verified by early Herpetic Eye Disease Study (HEDS) trials.

73 ata from 308 participants in the multicenter Herpetic Eye Disease Study between 1992 and 1998 (48% fe

74 t differences in visual outcome or recurrent herpetic eye disease were identified between the steroid

75 ions of people by reducing the prevalence of herpetic genital ulcer disease, but could also have an a

76 an HSCT patient who suffered from recurrent herpetic gingivostomatitis and was treated alternatively

77 l T cells to tissues protecting them against herpetic infection and disease.

78 rt an important role in host defense against herpetic infection for several polymorphic genes implica

79 There has been no recurrence of herpetic infection or OSSN during 10 months of follow-up

80 not seem to influence the clinical course of herpetic infection.

81 stem contributes to protection during ocular herpetic infection.

82 the severity of some symptoms associated to herpetic infections but neither remove the viral reservo

83 V-2 in patients presenting for evaluation of herpetic infections.

84 ecurrent symptom outbreaks that characterise herpetic infections.

85 cts who presented with recurrent, especially herpetic, infections and T-cell lymphopenia with impaire

86 Most common concomitant diagnoses included herpetic keratitis (33.70%), diabetes (31.59%), and corn

87 strategies to protect against HSK.IMPORTANCE Herpetic keratitis (HK) is the leading cause of blindnes

88 is superior to idoxuridine (IDU) in treating herpetic keratitis (HK) presenting as dendritic and geog

89 keratoplasty (PK) for keratoconus (n = 79), herpetic keratitis (n = 11), and granular dystrophy (n =

90 L-null mice showed significantly more severe herpetic keratitis (PI day 8, SLE score, mean +/- SEM: 3

91 eratopathy was associated most commonly with herpetic keratitis and diabetes.

92 ere examined daily for 49 days for recurrent herpetic keratitis and for recurrent infectious HSV-1 sh

93 ased number of eyes exhibited recurrences of herpetic keratitis compared with recurrences in adjuvant

94 Herpetic keratitis developed in all rabbits.

95 Liu et al. confirm prior literature that herpetic keratitis has higher recurrence rate in childre

96 uld be alert to the possibility of recurrent herpetic keratitis in patients treated with IFN-alpha 2b

97 latently infected rabbits with a history of herpetic keratitis to determine whether the viral DNA re

98 es of diabetes, corneal transplantation, and herpetic keratitis were associated significantly with wo

99 , corneal perforation, lacrimal obstruction, herpetic keratitis, and cytomegalovirus retinitis.

100 which the Boston KPro has been used include herpetic keratitis, aniridia, autoimmune ocular disorder

101 ror, corneal ectatic disorders, a history of herpetic keratitis, Avellino corneal dystrophy, signific

102 th regards to the way in which they manifest herpetic keratitis, making rapid diagnosis and treatment

103 neurotrophic keratitis, exposure keratitis, herpetic keratitis, ocular motor cranial neuropathies, a

104 To evaluate the severity of herpetic keratitis, slit lamp examinations (SLE) were pe

105 al presentation, diagnosis, and treatment of herpetic keratitis, with specific attention to pediatric

106 is, an essential step in the pathogenesis of herpetic keratitis.

107 une responses, including graft rejection and herpetic keratitis.

108 in the eye including allograft rejection and herpetic keratitis.

109 as of patients and animals with a history of herpetic keratitis.

110 She had no history of herpetic keratitis.

111 ry of diabetes, corneal transplantation, and herpetic keratitis.

112 ely due to the initial misdiagnosis of AK as herpetic keratitis.

113 Herpetic keratouveitis was suspected and intravenous acy

114 :0.16-0.32, p<0.001) but not the presence of herpetic lesions (beta = -0.10, 95%CI:-0.28-0.08, p = 0.

115 SV-2 seronegative women to 94% in women with herpetic lesions (geometric means 1634 vs 3339 copies/ml

116 act of herpetic lesions in humans.IMPORTANCE Herpetic lesions are a significant problem, and they are

117 Although virus strains isolated from herpetic lesions cause limited cell fusion in cell cultu

118 t also reduced the frequency and severity of herpetic lesions following intravaginal HSV challenge.

119 Our studies show that the severity of herpetic lesions in a mouse model can be diminished by c

120 approach to reducing the impact of recurrent herpetic lesions in humans.

121 exploring as a means to reduce the impact of herpetic lesions in humans.IMPORTANCE Herpetic lesions a

122 unodeficiency virus (HIV) infection, genital herpetic lesions may be extensive and tend to persist fo

123 ment the role of DCs in vitro and perhaps in herpetic lesions or draining lymph nodes.

124 imited cell fusion in cell culture, clinical herpetic lesions typically contain large syncytia, under

125 wise healthy African elephants with external herpetic lesions yielded herpesvirus sequences identical

126 ngal nail infection, fungal dermatitis, oral herpetic lesions, and bronchiolitis obliterans organizin

127 NK cells infiltrate human herpetic lesions, but their role has been underexplored.

128 V shedding with HIV plasma viral load (PVL), herpetic lesions, HSV shedding and other factors were ex

129 oxic responses were present at all stages of herpetic lesions, including biopsies early in the diseas

130 ted in early onset and delayed resolution of herpetic lesions, reduced viral clearance at the site of

131 rminants of genital HIV than the presence of herpetic lesions.

132 in the dermal infiltrate of human recurrent herpetic lesions.

133 .73 of HSV DNA are frequently recovered from herpetic lesions.

134 is characterized by systemic symptoms and no herpetic lesions.

135 contributing to acquisition of HIV-1 through herpetic lesions.

136 0 clinic visits who were never observed with herpetic lesions; (4) 18 HSV-2 seronegative women at 45

137 ercent) subsequently reported having typical herpetic lesions; the duration of their recurrences in t

138 keratoconus in its final stages, 3 had post-herpetic leukoma, and 5 had corneal scars.

139 Post-herpetic neuralgia (PHN) is the most significant complic

140 tudies on the incidence rates of HZ and post-herpetic neuralgia (PHN) since their introduction.

141 n and has serious consequences, notably post-herpetic neuralgia (PHN).

142 mechanisms involved in the genesis of acute herpetic neuralgia and open new avenues for its control.

143 he pathophysiological mechanisms involved in herpetic neuralgia are not totally elucidated.

144 TNF, via TNFR1, mediates herpetic neuralgia development through downregulation of

145 for its control.SIGNIFICANCE STATEMENT Acute herpetic neuralgia is the most important symptom of herp

146 Herpetic neuralgia is the most important symptom of herp

147 to the peripheral nervous system (e.g. post-herpetic neuralgia or diabetic neuropathy) or to the cen

148 F, which in turn mediates the development of herpetic neuralgia through downregulation of the inwardl

149 sory ganglia that account for the genesis of herpetic neuralgia using a murine model of Herpes Simple

150 9, 23); CNS infections, 12 (CI: 5, 13); post-herpetic neuralgia, 11 (CI: 6, 17); and major neurologic

151 in clinical trials for the treatment of post-herpetic neuralgia, diabetic peripheral neuropathy, gene

152 cted DRGs and account for the development of herpetic neuralgia.

153 ia that account for the development of acute herpetic neuralgia.

154 nglia play a critical role in the genesis of herpetic neuralgia.

155 zed mice, and were completely protected from herpetic ocular disease following corneal challenge with

156 is represents a useful adjunct to therapy of herpetic ocular disease, an important cause of human bli

157 the RCTs examined the use of adjuvant AMT in herpetic or Acanthamoeba keratitis, though the benefit w

158 mechanisms involved in the genesis of acute herpetic pain and open new avenues for its control.SIGNI

159 cal pain, diabetic neuropathic pain and post-herpetic pain.

160 mmunological evasion, viral persistence, and herpetic pathologies are determined by the regulation of

161 ty was consistently affected in both eyes of herpetic patients.

162 x thymidine kinase (AdV-tk) followed by anti-herpetic prodrug activation that promotes immunogenic tu

163 with minimal risk of immunologic rejection, herpetic recurrence and graft failure.

164 thelial cell density, immunologic rejection, herpetic recurrence, and graft failure rates.

165 r cumulative risk for immunologic rejection, herpetic recurrence, and graft failure was 9.7%, 7.8%, a

166 r experimental ultraviolet radiation-induced herpetic recurrences.

167 uced reactivation in the rabbit eye model of herpetic recurrent disease.

168 se patients with newly diagnosed or incident herpetic retinitis and choroiditis (rates = 21.7 deaths/

169 Eyes with newly diagnosed herpetic retinitis appeared to have a poor visual progno

170 5% confidence intervals [CI]) of these were: herpetic retinitis, 0.007/100 person-years (PY) (95% CI

171 In the murine model of herpetic retinitis, the same methods were used to compar

172 stic infections were diagnosed: 16 patients, herpetic retinitis; 11 patients, toxoplasmic retinitis;

173 Unilaterality was also more common in herpetic scleritis (80%) than in idiopathic disease (56.

174 We present the observed clinical features of herpetic scleritis and describe the clinical differences

175 Most patients with herpetic scleritis presented with acute (85.7%) and unil

176 itis was more commonly seen in patients with herpetic scleritis versus patients with idiopathic disea

177 uced corneal toxicity may be misdiagnosed as herpetic simplex keratitis (HSK).

178 We found that herpetic skin lesions consistently demonstrated oligoclo

179 7-fold reduction on the incidence of primary herpetic skin lesions in immunized animals.

180 Herpetic stromal keratitis (HSK) is a CD4+ T cell-contro

181 Herpetic stromal keratitis (HSK) is a painful and vision

182 Herpetic stromal keratitis (HSK) is an important vision-

183 Herpetic stromal keratitis (HSK) is an inflammatory dise

184 Herpetic stromal keratitis (HSK) is characterized by an

185 An immunoinflammatory blinding lesion called herpetic stromal keratitis (HSK) that follows ocular inf

186 mice to herpetic encephalitis as well as to herpetic stromal keratitis (HSK) was observed.

187 n immunopathologic disease of the eye termed herpetic stromal keratitis (HSK), in which the principal

188 Herpetic stromal keratitis (HSK), resulting from corneal

189 blinding immunoinflammatory lesion known as herpetic stromal keratitis (HSK).

190 ment of an immunopathological lesion, termed herpetic stromal keratitis (HSK).

191 valuated in a mouse model of human recurrent herpetic stromal keratitis (HSK).

192 induces an immunopathologic response termed herpetic stromal keratitis (HSK).

193 c inflammatory response in the stroma termed herpetic stromal keratitis (HSK).

194 munoinflammatory lesion in the cornea called herpetic stromal keratitis (HSK).

195 onse, leading to lesions in a disease called herpetic stromal keratitis (HSK).

196 arked reduction in the development of severe herpetic stromal keratitis (HSK).

197 returning to the cornea leading to recurrent herpetic stromal keratitis (rHSK).

198 matory and vision-impairing condition called herpetic stromal keratitis (SK).

199 tors in the cornea during the development of herpetic stromal keratitis as a means to alleviate furth

200 to determine whether established lesions of herpetic stromal keratitis could be controlled by topica

201 atitis and also indicate that the therapy of herpetic stromal keratitis could benefit by procedures t

202 re or after ocular HSV1 infection controlled herpetic stromal keratitis lesions.

203 f in vitro-differentiated MDSCs in dampening herpetic stromal keratitis resulting from primary ocular

204 We could show in three separate models of herpetic stromal keratitis that adoptive transfers of in

205 HSV-1 infections may lead to herpetic stromal keratitis that may advance to corneal b

206 -induced angiogenesis in the pathogenesis of herpetic stromal keratitis were experiments showing that

207 gies from HSV include the blindness-inducing herpetic stromal keratitis, highly debilitating and leth

208 This immunopathologic disease, called herpetic stromal keratitis, is an important cause of imp

209 epresent a vital step in the pathogenesis of herpetic stromal keratitis, these results indicate that

210 unoinflammatory lesion of the cornea, termed herpetic stromal keratitis.

211 ition should prove useful for the therapy of herpetic stromal keratitis.

212 o cause recurrent diseases, such as blinding herpetic stromal keratitis.

213 Vision loss was significantly greater in herpetic than idiopathic scleritis (34.3% vs 11.5%; P<0.

214 among HIV-1-seropositive participants with a herpetic ulcer.

215 were 295 HIV-1-positive participants with a herpetic ulcer.

216 ave long been recognized as being present in herpetic ulcerations, their role in subclinical reactiva

217 is commonly detected in the affected eyes of herpetic uveitis patients, suggesting the role of cross-